Core Viewpoint - Quantum Biopharma, Ltd. is facing a class action lawsuit for allegedly misleading investors during the Class Period from January 6, 2021, to October 15, 2025, with claims of stock price manipulation [1][2]. Group 1: Class Action Details - Investors who purchased Quantum securities during the specified Class Period have until February 23, 2026, to file a lead plaintiff motion [1]. - The lawsuit is being led by the Portnoy Law Firm, which offers complimentary case evaluations for affected investors [2]. Group 2: Allegations Against Defendants - The Complaint alleges that Defendants engaged in thousands of spoofed sell orders to create a false impression of a declining stock price for Quantum [2]. - These manipulative orders were intended to deceive investors into selling their shares at artificially low prices [2]. - Following the price decline, Defendants allegedly bought Quantum shares at these depressed levels, allowing them to profit from the scheme [2]. - As a result of these actions, investors were improperly induced to sell their shares at artificially depressed prices [2].